TY - JOUR
T1 - Risk factors for incident venous thromboembolism in active cancer patients
T2 - A population based case-control study
AU - Ashrani, Aneel A.
AU - Gullerud, Rachel E.
AU - Petterson, Tanya M.
AU - Marks, Randolph S.
AU - Bailey, Kent R.
AU - Heit, John A.
N1 - Funding Information:
We gratefully acknowledge Catherine L. Brandel, Diadra H. Else, Jane A. Emerson, and Cynthia L. Nosek for excellent data collection. Research reported in this publication was supported by a grant from the National Institutes of Health, National Heart Lung and Blood Institute ( R01HL66216 to JAH) and was made possible by the Rochester Epidemiology Project ( National Institutes of Health, National Institute on Aging ( R01AG034676 )). Research support also was provided by Mayo Foundation . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Funding Information:
Research reported in this publication was supported in part by grants from the National Heart Lung and Blood Institute under Award Number R01HL66216 to JAH, and was made possible by the Rochester Epidemiology Project (Award Number R01AG034676 of the National Institute on Aging, National Institutes of Health ). Research support also was provided by Mayo Foundation . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2016 Elsevier Ltd. All rights reserved.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Background Independent risk factors for cancer-associated incident venous thromboembolism (VTE) and their magnitude of risk are not fully characterized. Aim To identify non-cancer and cancer-specific risk factors for cancer-associated incident VTE. Methods In a population-based retrospective case-control study, we used Rochester Epidemiology Project and Mayo Clinic Cancer Registry resources to identify all Olmsted County, MN residents with active cancer-associated incident VTE, 1973-2000 (cases; n = 570) and 1-3 residents with active cancer matched to each case on age, sex, date and duration of active cancer (controls; n = 604). Using conditional logistic regression, we tested cancer and non-cancer characteristics for an association with VTE, including a cancer site VTE risk score. Results In the multivariable model, higher cancer site VTE risk score (OR = 1.4 per 2-fold increase), cancer stage ≥ 2 (OR = 2.2), liver metastasis (OR = 2.7), chemotherapy (OR = 1.8) and progesterone use (OR = 2.1) were independently associated with VTE, as were BMI < 18.5 kg/m2 (OR = 1.9) or ≥ 35 kg/m2 (OR = 4.0), hospitalization (OR = 7.9), nursing home confinement (OR = 4.7), central venous (CV) catheter (OR = 8.5) and any recent infection (OR = 1.7). In a subgroup analysis, platelet count ≥ 350 × 109/L at time of cancer diagnosis was marginally associated with VTE (OR = 2.3, p = 0.07). Conclusion Cancer site, cancer stage ≥ 2, liver metastasis, chemotherapy, progesterone, being underweight or obese, hospitalization/nursing home confinement, CV catheter, and infection are independent risk factors for incident VTE in active cancer patients.
AB - Background Independent risk factors for cancer-associated incident venous thromboembolism (VTE) and their magnitude of risk are not fully characterized. Aim To identify non-cancer and cancer-specific risk factors for cancer-associated incident VTE. Methods In a population-based retrospective case-control study, we used Rochester Epidemiology Project and Mayo Clinic Cancer Registry resources to identify all Olmsted County, MN residents with active cancer-associated incident VTE, 1973-2000 (cases; n = 570) and 1-3 residents with active cancer matched to each case on age, sex, date and duration of active cancer (controls; n = 604). Using conditional logistic regression, we tested cancer and non-cancer characteristics for an association with VTE, including a cancer site VTE risk score. Results In the multivariable model, higher cancer site VTE risk score (OR = 1.4 per 2-fold increase), cancer stage ≥ 2 (OR = 2.2), liver metastasis (OR = 2.7), chemotherapy (OR = 1.8) and progesterone use (OR = 2.1) were independently associated with VTE, as were BMI < 18.5 kg/m2 (OR = 1.9) or ≥ 35 kg/m2 (OR = 4.0), hospitalization (OR = 7.9), nursing home confinement (OR = 4.7), central venous (CV) catheter (OR = 8.5) and any recent infection (OR = 1.7). In a subgroup analysis, platelet count ≥ 350 × 109/L at time of cancer diagnosis was marginally associated with VTE (OR = 2.3, p = 0.07). Conclusion Cancer site, cancer stage ≥ 2, liver metastasis, chemotherapy, progesterone, being underweight or obese, hospitalization/nursing home confinement, CV catheter, and infection are independent risk factors for incident VTE in active cancer patients.
KW - Cancer
KW - Deep vein thrombosis
KW - Epidemiology
KW - Pulmonary embolism
KW - Risk factors
KW - Venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=84960075187&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960075187&partnerID=8YFLogxK
U2 - 10.1016/j.thromres.2016.01.002
DO - 10.1016/j.thromres.2016.01.002
M3 - Article
C2 - 26916293
AN - SCOPUS:84960075187
SN - 0049-3848
VL - 139
SP - 29
EP - 37
JO - Thrombosis Research
JF - Thrombosis Research
ER -